0000905148-24-000282.txt : 20240124 0000905148-24-000282.hdr.sgml : 20240124 20240124190106 ACCESSION NUMBER: 0000905148-24-000282 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240124 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walker Karin L CENTRAL INDEX KEY: 0001559422 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35676 FILM NUMBER: 24558250 MAIL ADDRESS: STREET 1: C/O PROTHENA CORPORATION PLC STREET 2: 650 GATEWAY BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO CENTRAL INDEX KEY: 0001559053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 BUSINESS PHONE: 011-353-1-236-2500 MAIL ADDRESS: STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C STREET 2: GRAND CANAL DOCKLANDS CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 FORMER COMPANY: FORMER CONFORMED NAME: Prothena Corp plc DATE OF NAME CHANGE: 20121102 FORMER COMPANY: FORMER CONFORMED NAME: Neotope Corp Ltd DATE OF NAME CHANGE: 20120926 4 1 form4.xml X0508 4 2024-01-24 0001559053 PROTHENA CORP PUBLIC LTD CO PRTA 0001559422 Walker Karin L C/O PROTHENA BIOSCIENCES INC 1800 SIERRA POINT PARKWAY BRISBANE CA 94005 true Chief Accounting Officer true Ordinary Shares, par value $0.01 per share 2024-01-24 4 M 0 5000 13.53 A 5000 D Ordinary Shares, par value $0.01 per share 2024-01-24 4 S 0 5000 34 D 0 D Stock Option (Right to Buy) 13.53 2024-01-24 4 M 0 5000 0 D 2029-02-27 Ordinary Shares 5000 15000 D The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. /s/ Michael J. Malecek, as Attorney-in-Fact for Karin L. Walker 2024-01-24